L
Lisa Patterson
Researcher at Institute of Cancer Research
Publications - 13
Citations - 2469
Lisa Patterson is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: In vivo & Angiogenesis. The author has an hindex of 12, co-authored 13 publications receiving 2259 citations.
Papers
More filters
Journal ArticleDOI
Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation
Maria Vinci,Sharon Gowan,F. E. Boxall,Lisa Patterson,Miriam Zimmermann,William Court,Cara Lomas,Marta Mendiola,David Hardisson,Suzanne A. Eccles +9 more
TL;DR: A suite of highly reproducible tumor microplate three-dimensional functional assays are established and validated to enhance the biological relevance of early preclinical cancer studies and increase the translational predictive value of in vitro drug evaluation studies and reduce the need for in vivo studies by more effective triaging of compounds.
Journal ArticleDOI
NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis
Suzanne A. Eccles,Andrew Massey,Florence I. Raynaud,Swee Y. Sharp,Gary Box,Melanie Valenti,Lisa Patterson,Alexis De Haven Brandon,Sharon Gowan,F. E. Boxall,Wynne Aherne,Martin G. Rowlands,Angela Hayes,Vanessa Martins,Frederique Urban,Kathy Boxall,Chrisostomos Prodromou,Laurence H. Pearl,Karen James,Thomas P. Matthews,Kwai-Ming Cheung,Andrew Kalusa,Keith Jones,Edward McDonald,Xavier Barril,Paul Brough,Julie E. Cansfield,Brian Dymock,Martin J. Drysdale,Harry Finch,Rob Howes,Roderick E. Hubbard,Alan Surgenor,Paul Webb,Michael Wood,Lisa Wright,Paul Workman +36 more
TL;DR: The data show that NVP-AUY922 is a potent, novel inhibitor of HSP90, acting via several processes (cytostasis, apoptosis, invasion, and angiogenesis) to inhibit tumor growth and metastasis.
Journal ArticleDOI
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.
Florence I. Raynaud,Suzanne A. Eccles,Paul A. Clarke,Angela Hayes,Bernard Nutley,Sonia Alix,Alan T. Henley,Francesca Di-Stefano,Zahida Ahmad,Sandrine Guillard,Lynn Bjerke,Lloyd R. Kelland,Melanie Valenti,Lisa Patterson,Sharon Gowan,Alexis De Haven Brandon,Masahiko Hayakawa,Hiroyuki Kaizawa,Tomonubu Koizumi,Takahide Ohishi,Sonal Patel,Nahid Saghir,Peter J. Parker,Mike Waterfield,Paul Workman +24 more
TL;DR: Despite its rapid in vivo metabolism, PI103 is a valuable tool compound for exploring the biological function of class I PI3K and importantly represents a lead for further optimization of this novel class of targeted molecular cancer therapeutic.
Journal ArticleDOI
A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity.
Sharon Gowan,John R. Harrison,Lisa Patterson,Melanie Valenti,Martin A. Read,Stephen Neidle,Lloyd R. Kelland +6 more
TL;DR: The antitelomerase and antitumor properties of a small-molecule compound designed by computer modeling to interact with and stabilize human G-quadruplex DNA, a structure that may form with telomeric DNA, thereby inhibiting access to telomerase, are described.
Journal ArticleDOI
In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors
Swee Y. Sharp,Kathy Boxall,Martin G. Rowlands,Chrisostomos Prodromou,S. Mark Roe,Alison Maloney,Marissa V. Powers,Paul A. Clarke,Gary Box,Sharon Sanderson,Lisa Patterson,Thomas P. Matthews,Kwai-Ming J. Cheung,Karen Ball,Angela Hayes,Florence I. Raynaud,Richard Marais,Laurence H. Pearl,Sue Eccles,Wynne Aherne,Edward McDonald,Paul Workman +21 more
TL;DR: Overall, it is shown that diaryl pyrazole resorcinols exhibited similar cellular properties to 17-AAG with potential advantages, and form the basis for further structure-based optimization to identify more potent inhibitors suitable for clinical development.